TGFB3 and neoplasm: Treating MSCs with recombinant TGFβ1 and TGFβ3 in the presence of FaDu CM led to significant inhibition of the observed phenotype at the cellular and molecular level (Figure 5c and d), which further implicated TGFβ signaling in negatively regulating MSC differentiation in response to tumor CM.